scispace - formally typeset
D

Dong Yin

Researcher at University of California, Los Angeles

Publications -  49
Citations -  3939

Dong Yin is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cell growth & Cell culture. The author has an hindex of 33, co-authored 41 publications receiving 3658 citations. Previous affiliations of Dong Yin include Memorial Hospital of South Bend & Cedars-Sinai Medical Center.

Papers
More filters
Journal ArticleDOI

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

TL;DR: Examining its antiproliferation, proapoptotic effects using three human glioblastoma multiforme cell lines and five primary GBM explants suggests that PS-341 may be an effective therapy for patients with gliomas.
Journal ArticleDOI

Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells

TL;DR: It is shown for the first time that cucurbitacin B has profound in vitro and in vivo antiproliferative effects against human pancreatic cancer cells, and the compound may potentate the antiprolifierative effect of the chemotherapeutic agent gemcitabine.
Journal ArticleDOI

Levels of Expression of CYR61 and CTGF Are Prognostic for Tumor Progression and Survival of Individuals with Gliomas

TL;DR: The results suggest that CYR61 and CTGF may play a role in the progression of gliomas; their levels at diagnosis may have prognostic significance; and these proteins might serve as valuable targets for therapeutic intervention.
Journal ArticleDOI

Short- and Long-term Outcomes after Laparoscopic and Open Hepatectomy for Hepatocellular Carcinoma: A Global Systematic Review and Meta-analysis

TL;DR: In patients with solitary left lateral lobe/right peripheral subcapsular tumors treated with minor resection, this meta-analysis demonstrated that compared to OH, LH may have short-term advantages in terms of blood loss and postoperative morbidity for HCC.